Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya33399Editorial articleПередовая статьяAcute renal failure induced by amphotericin В inthe treatment of invasive aspergillesis in patients with acutemyeloblasts leukemia (two case reports and review of literature)ОСТРАЯ ПОЧЕЧНАЯ НЕДОСТАТОЧНОСТЬ, ВЫЗВАННАЯ АМФОТЕРИЦИНОМ В,ПРИ ЛЕЧЕНИИ ИНВАЗИВНОГО АСПЕРГИЛЛЕЗА У БОЛЬНЫХ ОСТРЫМ МИЕЛОБЛАСТНЫМЛЕЙКОЗОМ (ОПИСАНИЕ ДВУХ СЛУЧАЕВ И ОБЗОР ЛИТЕРАТУРЫ)FilatovL BФилатовЛ Б

Городской гематологический центр; ЦГБ № 7, Екатеринбург

Городской гематологический центрЦГБ № 7, Екатеринбург15072003787NO7 (2003)ТОМ 78, №7 (2003)838613042020Copyright ©; 2003, Consilium MedicumCopyright ©; 2003, ООО "Консилиум Медикум"2003Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/33399

invasive ospergillesisjebrile neutropeniaacute renal failureamphotericin Bacute myeloblasts leukemianephrotoxicityинвазивный аспергиллезагранулоцитозострый лейкозамфотерицин Вострая почечная недостаточностьнефротоксичностъWarnock D. W. Fungal infections in neutropenia: current problems and chemotherapeutic control. J. Antimicrob. Chemother. 1998; 41 (suppl. D): 95-105.Lin S.-J., Schranz J., Teutsch S. M. Aspergillosis case-fatality rate: systemic review of the literature. Clin. Infect. Dis. 2001; 32: 358-366.Latge J.-P. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 1999; 12: 310-350.Климко Н. Н., Митрофанов В. С., Перекатова Т. Н. и др. Инвазивный аспергиллез у больных гемобластозами: описание шести случаев. Пробл. мед. микол. 1999; 1 (1): 32- 39.Bow Е., J. Invasive aspergillosis in cancer patients. Oncology 2001; 15 (8): 1035-1047.Gerson S. L., Talbot G. H., Hervitz S. et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann. Intern. Med. 1984; 100: 345-351.Grow W. В., Moreb J. S., Roque D. et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant. 2002; 29: 15- 19.Stevens D. A., Kan V. L., Judson M. A. et al. Practice guidelines for diseases caused by aspergillus. Clin. Infect. Dis. 2000; 30: 676-709.Sheehan D. J., Hitchcock Ch. A., Sibley С. M. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 1999; 12(1): 40-79.Deray G. Amphotericin В nephrotoxicity. J. Antimicrob. Chemother. 2002; 49 (Suppl. SI): 37-41.Wingard J. R., Kubilis P., Lee L. et al. Clinical significance of nephrotoxicity in patients treated with amphotericin В for suspected or proven aspergillosis. Clin. Infect. Dis. 1999; 29: 1402-1407.Cannon J. P., Garey K. W., Danziger L. H. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin В formulations. Pharmacotherapy 2001; 21 (9): 1107-1114.Bates D. W., Su L., Yu D. T. et al. Mortality and costs of acute renal failure associated with amphotericin В therapy. Clin. Infect. Dis. 2001; 32: 686-693.Harbarth S., Pestotnik S. L., Lloid J. F. et al. The epidemiology of nephrotoxicity associated with conventional amphotericin В therapy. Am. J. Med. 2001; 111: 528-534.Richardson M. D., Warnock D. W. Fungal infection: diagnosis and management. 2nd ed. Oxford: Blackwell Science; 1997.Fisher M. A., Talbot G. H., Maislin G. et al. Risk factors for amphotericin B-associated nephrotoxicity. Am. J. Med. 1989; 87:547-552.Gubbins P. O., Penzak S. R., Polston S. et al. Characterizing and predicting amphotericin В - associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002; 22 (8): 961-971.Luber A. D., Maa L., Lam M., Guglielmo B. J. Risk factor amphotericin В - induced nephrotoxicity. J. Antimicrob. Chemother. 1999; 43: 267-271Nally J. V. Jr. Acute renal failure in hospitalized patients. Cleveland Clin. i. Med. 2002; 69 (7): 569-574.Walsh J. W., Finberg R. W., Arndt С. et al. Lyposomal amphotericin В for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 1999; 340: 764-771.Mayer J., Doubek M., Doubek J. et al. Reduced nephrotoxicity of conventional amphotericin В therapy after minima! nephroprotective measures: animal experiments and clinical study. J. Infect. Dis. 2002; 186 (3): 379-388.Davits H. D., King S. M., Doyle J. et al. Controlled pilot study of rapid amphotericin В infusions. Arch. Dis. Childh. 1997; 76: 165-166.Eriksson U., Seifert В., Schaffner A. Comparison of effects of amphotericin В deoxycholate infused over 4 or 24 hours: randomised controlled trial. Br. Med. J. 2001; 322: 579-582.Furrer K., Schaffner A., Vavricka S. R. et al. Nephrotoxicity of cyclosporine A and amphotericin В - deoxycholate as continuous infusion in allogeneic stem cell transplantation. Swiss. Med. Wkly 2002; 132: 316-320.Camp M. J., Wingard J. R., Gilmore С. Е. et al. Efficacy of low-dose dopamine in preventing amphotericin В nephrotoxicity in bone marrow transplant patients and leukemia patients. Antimicrob. Agents Chemother. 1998; 42 (12): 3103-3106.Salama S., Rotstein С. Reduction in the nephrotoxicity of amphotericin В when administered in 20% intralipid. Can. J. Infect. Dis. 1997; 8 (3): 157-160.Heinemann V., Kahny В., Jehn U. et al. Serum pharmacology of amphotericin В applied in lipid emulsions. Antimicrob. Agents Chemother. 1997; 41 (4): 728-732.Schoffski P., Freund M., Wander R. et al. Safety and toxicity of amphotericin В in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. Br. Med. J. 1998; 317 (8): 379-384.Nucci M., Loureiro M., Silveira F. et al. Comparison of the toxicity of amphotericin В in 5% dextrose with that of amphotericin В in fat emulsion in a randomized trial with cancer patients. Antimicrob. Agents Chemother. 1999; 43 (6): 1445- 1448.Nath Ch. E., Shaw P. J., Gunning R. et al. Amphotericin В in children with malignant disease: a comparison of the toxicities and pharmacokinetics of Amphotericin В administered in dextrose versus lipid emulsion. Ibid. 1417-1423.Wingard J. R., White M. H., Anaissie E. et al. A randomized, double-blind comparitive trial evaluating the safety of liposomal amphotericin В versus amphotericin В lipid complex in the empirical treatment of febrile neutropenia. Clin. Infect. Dis. 2000; 31: 1155-1163.Савченко В. Г., Паровичникова Е. Н., Клясова Г. А. и др, Итоги многоцентрового исследования по лечению острых миелоидных лейкозов взрослых. Тер. арх. 1994; 66 (7): 11-17.Myoken У., Sugata Т., Kyo T.-L et al. Invasive aspergillus stomatitis in patients with acute leukemia: report of 12 cases. Clin. Infect. Dis. 2001; 33: 1975-1980.Verweij P. E., Stynen D., Rus A. J. M. M. et al. Sandwich enzyme-linked immunosorbent assay compared with Pastorex la- tex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J. Clin. Microbiol. 1995; 33: 1912-1914.Bodey G. P. Fungal infection in neutropenic patients: past achivements and future problems. In: Klastersky J. A., ed. Febrile neutropenia. New York: Springer; 1997: 89-98.Roilides E., Farmaki E. Granulocyte Colony-stimulating factor and other cytokines in antifungal therapy. Clin. Microbiol. Infect. 2001; 7 (suppl. 2): 62-67.